Welcome to our dedicated page for AN2 Therapeutics SEC filings (Ticker: ANTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AN2 Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule therapeutics from a boron chemistry platform. Its disclosures cover common stock registration, operating and financial results, clinical and regulatory updates, risk factors and material events related to its development pipeline.
ANTX filings also include proxy materials for director elections and auditor ratification, 8-K reports on material agreements, equity and warrant financing arrangements, at-the-market sale agreements, equity incentive plan matters, option repricing, officer appointments, governance changes and capital-structure disclosures.
AN2 Therapeutics director Patricia A. Martin reported a repricing of several stock options on March 19, 2026. She disposed of three existing options to purchase 24,999, 10,362 and 23,742 shares of common stock at exercise prices of $6.596, $17.28 and $5.91 per share, respectively, and received new, fully vested options for the same share amounts at an exercise price of $3.91 per share.
According to the board-approved terms, the $3.91 exercise price equals the closing stock price on the repricing date and will revert to each option’s original exercise price if the repriced option is exercised or her service ends before the “Premium End Date,” defined as the earliest of September 19, 2027, a change in control, or her death or disability.
AN2 Therapeutics director Margaret M. FitzPatrick reported a board-approved repricing of stock options on the company’s common stock. On March 19, 2026, existing options were surrendered to the issuer and replaced with new fully vested options covering the same number of shares at an exercise price of $3.91 per share.
The repricing keeps all other terms unchanged, except that the exercise price will revert to the original higher level if the repriced options are exercised, or if her service ends, before the “Premium End Date.” The Premium End Date is the earliest of September 19, 2027, a change in control, or her death or disability.
AN2 Therapeutics director Stephanie Wong reported a repricing of multiple stock options on the company’s common stock. On March 19, 2026, she was granted new stock options covering 24,999, 10,362 and 23,742 shares at an exercise price of $3.91 per share, matching the closing market price that day. In corresponding transactions, options over the same numbers of shares with higher exercise prices of $6.596, $17.28 and $5.91 were surrendered to the company.
According to the footnotes, the repriced option is fully vested. The $3.91 exercise price will be increased back to the original exercise price if, before the stated “Premium End Date,” the repriced option is exercised or Wong’s service with the company ends.
AN2 Therapeutics director Joseph S. Zakrzewski reported a board-approved repricing of his stock options. On March 19, 2026, existing options to buy common stock with higher exercise prices were surrendered to the company and replaced with new fully vested options at an exercise price of $3.91 per share.
The new options cover multiple grants of stock options (rights to buy common stock) with expiration dates ranging from April 29, 2031 to June 6, 2033. The filing reflects compensation-related adjustments only and does not show any open-market purchases or sales of AN2 Therapeutics common stock.
AN2 Therapeutics, Inc. reported that officer Joshua M. Eizen had certain stock options repriced on March 19, 2026. He received new options to purchase 92,000 and 50,150 shares of common stock at an exercise price of $3.91 per share, replacing prior options for the same share amounts with higher exercise prices of $17.88 and $14.29.
The footnotes explain that the new exercise price equals the closing market price on the repricing date and that vesting schedules remain as previously set. The filing shows no open-market purchases or sales of common stock, only compensation-related option grants and corresponding cancellations back to the issuer.
AN2 Therapeutics director Melvin K. Spigelman reported a board-approved repricing of his stock options on March 19, 2026. He received three fully vested stock option awards for 16,941, 10,362 and 23,742 underlying common shares at a new exercise price of $3.91 per share, while surrendering an equal number of existing options with higher exercise prices of $9.308, $17.28 and $5.91.
The repriced options keep their original terms except for the exercise price. If any repriced option is exercised, or his service ends, before the “Premium End Date” (the earliest of September 19, 2027, a change in control, or his death or disability), the exercise price reverts to the original higher level. These are compensation-related derivative adjustments, not open-market stock purchases or sales.
AN2 Therapeutics director Robin Shane Readnour reported a repricing of stock options covering 20,724 and 23,742 shares of common stock on March 19, 2026. Existing options with exercise prices of $17.28 and $5.91 per share were returned to the company, and fully vested replacement options were granted at an exercise price of $3.91 per share, equal to the closing stock price on the repricing date.
The footnotes state this new exercise price will revert to the original higher price if the repriced options are exercised, or if Readnour’s service with the company ends, before the defined “Premium End Date,” which is the earliest of September 19, 2027, a change in control, or Readnour’s death or disability.
AN2 Therapeutics Chief Executive Officer Eric Easom reported a repricing of his stock options, with no open-market purchases or sales of common stock. On March 19, 2026, the board approved cancelling existing options with exercise prices of $6.596, $17.28 and $11.99 per share and granting replacement options over the same share amounts at an exercise price of $3.91 per share, matching the closing stock price that day.
The replacement options remain subject to their original expiration dates and vesting schedules, including monthly vesting measured from March 25, 2022 and January 1, 2023, as applicable. The footnotes state that if the repriced options are exercised, or Easom’s service ends, before a defined “Premium End Date,” the exercise price will revert to the original higher levels.
AN2 Therapeutics, Inc. approved a broad stock option repricing on March 19, 2026. All outstanding options granted under its 2017 and 2022 equity incentive plans before that date now have an exercise price of $3.91 per share, matching the common stock closing price on the repricing date.
Holders must still pay the original exercise price if they exercise before the “Premium End Date,” defined as the earliest of September 19, 2027, a change in control, or the holder’s death or disability. All other terms of the options remain unchanged. Named executive officers affected include CEO Eric Easom with 742,649 repriced options, CLO/COO Joshua Eizen with 142,150 options, and CFO Lucy Day with 221,965 options, originally priced between $6.60 and $17.88 per share.
AN2 Therapeutics, Inc. provides an annual overview as a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform. Its lead candidate, oral epetraborole, is being advanced toward Phase 2 studies in phlebotomy-dependent polycythemia vera and Mycobacterium abscessus complex lung disease.
The company is also developing oral AN2-502998 for Chagas disease, with a Phase 1 trial in healthy volunteers nearing completion and a proof-of-concept Phase 2 planned in 2026. Preclinical oncology programs target PI3Kα and ENPP1, with two oncology candidates expected to enter development in 2026, alongside global health programs in melioidosis and tuberculosis funded largely by non-dilutive sources.
AN2 operates via an asset-light model, outsourcing manufacturing and relying on key license agreements with Anacor, Brii Biosciences, Adjuvant Global Health Technology Fund and the University of Georgia Research Foundation. As of June 30, 2025, non-affiliate equity had an aggregate market value of $23,078,812, and 35,941,195 common shares were outstanding as of March 10, 2026.